Curriculum Vitae

ASSOCIATE PROF. DR. ADLINDA BINTI ALIP

Associate Professor
  • Department of Oncology Clinical
    Faculty of Medicine
  • adlinda
  • 0379493015

BIOGRAPHY

Dr Adlinda graduated from Southampton University, UK and completed general medical training before being awarded the MRCP by the Royal College of Physician, UK. She obtained FRCR by the Royal College of Radiologist (Clinical Oncology) UK and awarded certificate of completion (CCT) in Clinical Oncology by General Medical Council UK in 2011. She joined University of Malaya as a Senior Lecturer and Clinical Oncologist in 2012. She is a principal and sub investigator for several ongoing and completed clinical trials. She gives talks and presentation locally and in international meetings. Her main areas of interest include Lung, Breast, Genitourinary and Stereotactic Radiosurgery/Radiotherapy.

ACADEMIC QUALIFICATION

  • FRCR (Clinical Oncology), (Onkology Clinical)
    Royal College of Radiologist, London
  • MRCP, (Medicine)
    Royal College of Physicians of Edinburgh, United Kingdom
  • BMed, (Medicine)
    Southampton University, UK

ADMINISTRATIVE DUTIES

  • Committee member of Stereotactic Body Radiotherapy to Spine
    17 Dec 2015 - present (Department of Oncology, Faculty of Medicine)
  • Group leader for Genitourinary Group for the update/revision of National Chemotherapy Guidelines
    02 Apr 2014 - present (National)
  • Committee member of UMMC electronic medical records committee
    05 May 2014 - present (Department of Oncology, Faculty of Medicine)
  • Member of a committee to set up new service which is stereotactic radiosurgery. Developing/adapting protocol for the service.
    14 Feb 2014 - present (Department of Oncology, Faculty of Medicine)
  • Committee member to revise radiotherapy logbook for Master of Clinical Oncology
    05 Sep 2012 - present (Department of Oncology, Faculty of Medicine)
  • Member of a committee developing Radiotherapy Information Booklet for patients.
    03 Jan 2014 - present (Department of Oncology, Faculty of Medicine)
  • Ahli Jawatankuasa Pelaksana Pengurusan Strategik 3
    02 Jan 2021 - 31 Dec 2023 (National)
  • Course Coordinator
    14 Jul 2021 - 14 Jul 2023 (University Malaya)
  • AHLI JAWATANKUASA PENGURUSAN DAN TEKNIKAL CIGMIT
    29 Sep 2020 - 30 Sep 2022 (National)
  • Head
    06 Mar 2019 - 05 Mar 2021 (Clinical Oncology Unit, Faculty of Medicine)
  • Member of Editorial Board of International Clinical Medicine and Surgery
    23 Feb 2021 - 31 Dec 2021 (International)
  • AHLI JAWATANKUASA PENASIHAT PERUBATAN
    01 Jan 2020 - 31 Dec 2021 (University Malaya)
  • AHLI JAWATANKUASA TEKNIKAL KIMOTERAPI
    10 Dec 2019 - 31 Dec 2021 (National)
  • AHLI JAWATANKUASA UMMC CANCER REGISTRY
    04 Nov 2020 - 30 Nov 2021 (National)
  • EXPERT COMMITTEE FOR BONE TARGETING AGENTS IN PREVENTING SKELETAL RELATED EVENTS FOR METASTATIC CANCERS IN SOLID TUMORS
    01 Oct 2020 - 31 Oct 2021 (National)
  • UM Specialist Centre Medical and Dental Advisory Committee (MDAC)
    10 Jun 2019 - 10 Jun 2021 (University Malaya)
  • AHLI JAWATANKUASA PENASIHAT PERUBATAN PPUM
    01 Apr 2019 - 30 Apr 2021 (National)
  • Member of Advisory Development of Guidelines for Centre of Excellence (COE) in Healthcare Facility in Malaysia
    04 Apr 2021 - 05 Apr 2021 (National)
  • IPT Evaluation Panel
    27 Feb 2021 - 31 Mar 2021 (National)
  • JAWATANKUASA BERSAMA KEPAKARAN
    17 Mar 2020 - 31 Mar 2021 (National)
  • Deputy Head
    06 Mar 2019 - 01 Mar 2021 (University Malaya)
  • Menjalankan Fungsi Sebagai Penyelaras Program
    07 Mar 2019 - 01 Mar 2021 (University Malaya)
  • COMMITTEE MEMBERS VIRTUAL AEROBICTON 2021
    27 Feb 2021 - 27 Feb 2021 (National)
  • Editors and Editorial Board of the journal (Wiley)
    19 Feb 2021 - 19 Feb 2021 (International)
  • Chairman
    11 Sep 2020 - 12 Sep 2020 (National)
  • Research Coordinator
    14 Aug 2017 - 31 Dec 2019 (Department of Oncology, Faculty of Medicine)
  • Menjalankan Fungsi Sebagai Penyelaras Program
    14 Aug 2017 - 31 Dec 2019 (University Malaya)
  • Chairman
    02 May 2019 - 03 May 2019 (University Malaya)
  • INTERNAL EXAMINER FOR DOCTORAL THESIS EXAMINATION
    26 Apr 2019 - 26 Apr 2019 (University Malaya)
  • Trainer
    23 Mar 2019 - 24 Mar 2019 (National)
  • EXPERT COMMITTEE FOR BONE TARGETING AGENTS IN PREVENTING SKELETAL RELATED EVENTS FOR METASTATIC CANCERS IN SOLID TUMORS
    20 Nov 2017 - 31 Dec 2018 (National)
  • committee member of Root Cause Analysis
    12 Apr 2018 - 31 Dec 2018 (National)
  • Committee member for Clinical Oncology Specialty Committee for Masters of Clinical Oncology
    18 Dec 2017 - 18 Dec 2018 (National)
  • Coordinator
    01 Jul 2017 - 01 Dec 2018 (Department of Oncology, Faculty of Medicine)
  • Committee member of Section of URo-Oncology Forum 2018
    30 Jun 2018 - 01 Jul 2018 (National)
  • Committee member of technical advisor for new accelerator
    18 May 2016 - 18 Sep 2017 (University Malaya)
  • Committee member for First IAEA National Training Course on IMRT
    25 Feb 2016 - 31 Jul 2016 (National)
  • Member of academics committee for clinical oncology unit
    02 Sep 2013 - 07 Sep 2015 (Department of Oncology, Faculty of Medicine)

MEMBERSHIPS

  • MALAYSIAN ONCOLOGY SOCIETY, MEMBER
    Since 2014 (National)
  • MALAYSIAN ONCOLOGICAL SOCIETY- LIFETIME MEMBERSHIP, MEMBER
    Since 2012 (National)
  • GENERAL MEDICAL COUNCIL, UNITED KINGDOM, MEMBER
    Since 2011 (International)
  • CERTIFICATE OF COMPLETION FROM GMC, MEMBER
    Since 2011 (International)
  • ROYAL COLLEGE OF RADIOLOGIST, FELLOW
    Since 2010 (International)
  • FULL MEMBER, MEMBER
    2016 to 2024 (International)
  • MEMBER OF IASLC, MEMBER
    2022 to 2023 (International)
  • COLLABORATOR, RESEARCHER, MEMBER
    2022 to 2023 (International)
  • MEMBER OF ACADEMY OF MEDICINE MALAYSIA, MEMBER
    2020 to 2022 (National)
  • ACADEMY OF MEDICINE OF MALAYSIA, ORDINARY MEMBER
    2020 to 2021 (National)
  • MALAYSIAN MEDICAL COUNCIL, MEMBER OF PROGRAM ADVISORY COMMITTEE
    2020 to 2021 (National)
  • EUROPEAN SOCIETY OF MEDICAL ONCOLOGY, ORDINARY MEMBER
    2015 to 2018 (University)
  • EUROPEAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY (ESTRO), MEMBER
    2013 to 2014 (International)

AWARD AND STEWARDSHIP

  • Certificate of Excellent Service
    2021, Universiti Malaya
  • Reviewer for Asia Pacific Journal of Clinical Oncology
    2017, Asia Pacific Journal of Clinical Oncology,  (Private)
  • Certificate of Excellent Service
    2017, Universiti Malaya
  • Certificate of Excellent Service
    2016, Universiti Malaya
  • Certificate of Appreciation -Surf 2014 - Section of Uro-Oncology Forum
    2014, Malaysia,  (International)
  • Pfizer Oncology Workshop: Winning Oncology Way Rcc 2014
    2014, Pfizer Oncology, Malaysian Oncologist Malaysia,  (International)
  • Certificate of Appreciation & Attendance- 2013 Joint Scientific Meeting:Mscoskeletal Imaging and Oncology
    2014, College of Radiology , Malaysian Oncological Society,Malaysian Society of Radiology,  (International)
  • Ascomos: Annual Scientific Congress of The Malaysian Oncological Society
    2013, Malaysian Oncology Society,  (International)
  • Certificate of Achievement-Night Run 2013
    2013, Men Health Malaysia, Health Today Malaysia,  (National)
  • Penang Bridge International Marathon- Medal and Certificate
    2013, Association of International Marathon and Distance Races, Penang Amateur Athletic Association, Penang Government,  (International)
  • 21st Malaysian Urological Conference
    2012, Joint Malaysian-Scottish Urological Conference,  (International)

PUBLICATIONS

Article in Journal
WoS
  1. Cho, Byoung C.; Lu, Shun; Felip, Enriqueta; Spira, Alexander I.; Girard, Nicolas; Lee, Jong-Seok; Lee, Se-Hoon; Ostapenko, Yurii; Danchaivijitr, Pongwut; Liu, Baogang; Alip, Adlinda; Korbenfeld, Ernesto; Mourao Dias, Josiane; Besse, Benjamin; Lee, Ki-Hyeong; Xiong, Hailin; How, Soon-Hin; Cheng, Ying; Chang, Gee-Chen; Yoshioka, Hiroshige; Yang, James C. -H.; Thomas, Michael; Nguyen, Danny; Ou, Sai-Hong I.; Mukhedkar, Sanjay; Prabhash, Kumar; D'Arcangelo, Manolo; Alatorre-Alexander, Jorge; Vazquez Limon, Juan C.; Alves, Sara; Stroyakovskiy, Daniil; Peregudova, Marina; Sendur, Mehmet A. N.; Yazici, Ozan; Califano, Raffaele; Gutierrez Calderon, Vanesa; de Marinis, Filippo; Passaro, Antonio; Kim, Sang-We; Gadgeel, Shirish M.; Xie, John; Sun, Tao; Martinez, Melissa; Ennis, Mariah; Fennema, Elizabeth; Daksh, Mahesh; Millington, Dawn; Leconte, Isabelle; Iwasawa, Ryota; Lorenzini, Patricia; Baig, Mahadi; Shah, Sujay; Bauml, Joshua M.; Shreeve, S. Martin; Sethi, Seema; Knoblauch, Roland E.; Hayashi, Hidetoshi (2024). Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC, NEW ENGLAND JOURNAL OF MEDICINE. 391(16), 1486-1498. doi:10.1056/NEJMoa2403614
  2. Felip, E.; Cho, B. C.; Gutierrez, V; Alip, A.; Besse, B.; Lu, S.; Spira, A. I.; Girard, N.; Califano, R.; Gadgeel, S. M.; Yang, J. C-H.; Yamamoto, S.; Azuma, K.; Kim, Y. J.; Lee, K. -H.; Danchaivijitr, P.; Ferreira, C. G.; Cheng, Y.; Sendur, M. A. N.; Chang, G. -C.; Wang, C. -C.; Prabhash, K.; Shinno, Y.; Stroyakovskiy, D.; Paz-Ares, L.; Rodriguez-Cid, J. R.; Martin, C.; Campelo, M. R. G.; Hayashi, H.; Nguyen, D.; Tomasini, P.; Gottfried, M.; Dooms, C.; Passaro, A.; Schuler, M.; Gelatti, A. C. Z.; Owen, S.; Perdrizet, K.; Ou, S. -H. I.; Curtin, J. C.; Zhang, J.; Gormley, M.; Sun, T.; Panchal, A.; Ennis, M.; Fennema, E.; Bauml, J. M.; Daksh, M.; Sethi, S.; Lee, S. -H. (2024). Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA, ANNALS OF ONCOLOGY. 35(9), 805-816. doi:10.1016/j.annonc.2024.05.541
  3. Felip, Enriqueta; Cho, Byoung Chul; Gutierrez, Vanesa; Alip, Adlinda; Besse, Benjamin; Lu, Shun; Spira, Alexander I.; Girard, Nicolas; Califano, Raffaele; Gadgeel, Shirish M.; Yang, James Chih-Hsin; Nogami, Naoyuki; Azuma, Koichi; Curtin, Joshua C.; Zhang, Jiarui; Panchal, Anesh; Ennis, Mariah; Sethi, Seema Niphadkar; Bauml, Joshua Michael; Lee, Se-Hoon (2024). Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study, JOURNAL OF CLINICAL ONCOLOGY. 42(16)
  4. Ab Muin, Nur Fa'Izah; Saad, Marniza; Alip, Adlinda; Thiagarajan, Muthukkumaran (2023). The outcomes of glioblastoma multiforme: The University Malaya Medical Centre experience 2008-2018, ANNALS OF ONCOLOGY. 34, S1411-S1411. doi:10.1016/j.annonc.2023.09.213
  5. Cho, B. C.; Felip, E.; Spira, A. I.; Girard, N.; Lee, J. S.; Lee, S. H.; Ostapenko, Y. V.; Danchaivijitr, P.; Liu, B.; Alip, A.; Korbenfeld, E. P.; Dias, J.; Sun, T.; Martinez, M.; Bauml, J. M.; Shreeve, M.; Sethi, S.; Knoblauch, R. E.; Hayashi, H.; Lu, S. (2023). Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial, ANNALS OF ONCOLOGY. 34, S1306-S1306. doi:10.1016/j.annonc.2023.10.062
  6. Teng, Qing Yong; Saad, Marniza; Alip, Adlinda; Yeoh, Wei Sien; Kuppusamy, Shanggar; Ong, Teng Aik (2023). Real-world utilisation of prostate-specific membrane antigen (PSMA) PET-CT in patients with prostate cancer at a tertiary referral centre in Kuala Lumpur, BJU INTERNATIONAL. 132(SUPP2), 29-29
  7. Zahir, Nur Syazana Mohd; Saad, Marniza; Alip, Adlinda; Rejab, Munira; Jamalludin, Zulaikha; Hizam, Nur Diyana Afrina; Liew, Yih Miin; Ung, Ngie Min (2023). Evaluation of intrafractional prostate displacement during prostate radiotherapy using real-time ultrasound system, PHYSICAL AND ENGINEERING SCIENCES IN MEDICINE. . doi:10.1007/s13246-023-01230-x
  8. Ho, Gwo Fuang; Lee, Soo-Chin; Lim, Joanna; Bustam, Anita Zarina; Lim, Siew Eng; Saad, Marniza; Ow, Samuel Guan Wei; Ngoi, Natalie; Satar, Nur Fadhlina Abdul; Malik, Rozita Abdul; Alip, Adlinda; Law, Kian Boon; Toh, Yok Yong; Pan, Jia Wern; Teo, Soo Hwang (2022). A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR)., JOURNAL OF CLINICAL ONCOLOGY. 40(16)
  9. Jalil, N. B.; Lee, P. Y.; Nor Afiah, M. Z.; Abdullah, K. L.; Azizi, F. N. S. Mohd; Rassip, N. N. S. Abdul; Ong, T. A.; Ng, C. J.; Lee, Y. K.; Cheong, A. T.; Razack, A. H.; Saad, M.; Alip, A.; Malek, R.; Sundram, M.; Omar, S.; Sathiyananthan, J. R.; Kumar, P. (2022). Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country, JOURNAL OF CANCER EDUCATION. . doi:10.1007/s13187-020-01801-6
  10. Lee, Ping Yein; Cheong, Ai Theng; Ghazali, Sazlina Shariff; Rashid, Aneesa Abdul; Ong, Siu Ching; Ong, Soo Ying; Alip, Adlinda; Sylvia, McCarthy; Chen, May Feng; Taib, Nur Aishah; Jaganathan, Maheswari; Ng, Chirk Jenn; Teo, Soo-Hwang (2022). Barriers of and strategies for shared decision-making implementation in the care of metastatic breast cancer: A qualitative study among patients and healthcare professionals in an Asian country, HEALTH EXPECTATIONS. . doi:10.1111/hex.13590
  11. Schutz, F. A. B., Sirachainan, E., Kuppusamy, S., Hoa, N. T. T., Dejthevaporn, T., Bahadzor, B., . . . Garg, A. (2021). Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel. Therapeutic Advances in Medical Oncology, 13, 13. doi: 10.1177/1758835920985464
  12. Chai, C. S., Liam, C. K., Poh, M. E., Ong, D. B. L., Pang, Y. K., Cheah, P. L., . . . Alip, A. (2020). Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Cancer Management and Research, 12, 5439-5450. doi: 10.2147/cmar.s253760
  13. Chai, C. S., Liam, C. K., Poh, M. E., Ong, D. B. L., Pang, Y. K., Cheah, P. L., . . . Alip, A. (2020). Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Cancer Management and Research, 12, 5439-5450. doi: 10.2147/cmar.s253760
  14. Lim, J., Amantakul, A., Shariff, N., Lojanapiwat, B., Alip, A., Ong, T. A., . . . Saad, M. (2020). Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort. Cancer Medicine, 9(13), 4613-4621. doi: 10.1002/cam4.3101
  15. Park, K., Vansteenkiste, J., Lee, K. H., Pentheroudakis, G., Zhou, C., Prabhash, K., . . . Douillard, J. Y. (2020). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Annals of Oncology, 31(2), 191-201. doi: 10.1016/j.annonc.2019.10.026
  16. Ho, G. F., Chai, C. S., Alip, A., Wahid, M. I. A., Abdullah, M. M., Foo, Y. C., . . . Liam, C. K. (2019). Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. Bmc Cancer, 19(1), 11. doi:10.1186/s12885-019-6107-1
  17. Saad, M., Alip, A., Lim, J., Abdullah, M. M., Chong, F. L. T., Chua, C. B., . . . Ong, T. A. (2019). Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. Bju International, 124(3), 373-382. doi:10.1111/bju.14807
  18. Wu, Y. L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D. W., . . . Douillard, J. Y. (2019). Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Annals of Oncology, 30(2), 171-210. doi:10.1093/annonc/mdy554
  19. Abd Ghafar, N. K., Alip, A., Ong, T. A., Yap, N. Y., Saad, M. (2018). Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience. Journal of Cancer Research and Therapeutics, 14(6), 1303-1311. doi:10.4103/0973-1482.189247
Scopus
  1. Ab Muin N.F., Saad M., Alip A., Thiagarajan M. (2024). THE OUTCOMES OF GLIOBLASTOMA MULTIFORME: THE UNIVERSITY MALAYA MEDICAL CENTRE EXPERIENCE 2008-2018, Journal of Health and Translational Medicine. 27(1), 49-56. doi:10.22452/jummec.vol27no1.7
  2. Felip E., Cho B.C., Gutierrez V., Alip A., Besse B., Lu S., Spira A.I., Girard N., Califano R., Gadgeel S.M., Yang J.C.-H., Yamamoto S., Azuma K., Kim Y.J., Lee K.-H., Danchaivijitr P., Ferreira C.G., Cheng Y., Sendur M.A.N., Chang G.-C., Wang C.-C., Prabhash K., Shinno Y., Stroyakovskiy D., Paz-Ares L., Rodriguez-Cid J.R., Martin C., Campelo M.R.G., Hayashi H., Nguyen D., Tomasini P., Gottfried M., Dooms C., Passaro A., Schuler M., Gelatti A.C.Z., Owen S., Perdrizet K., Ou S.-H.I., Curtin J.C., Zhang J., Gormley M., Sun T., Panchal A., Ennis M., Fennema E., Daksh M., Sethi S., Bauml J.M., Lee S.-H. (2024). Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA, Annals of Oncology. . doi:10.1016/j.annonc.2024.05.541
  3. Zahir N.S.M., Saad M., Alip A., Rejab M., Jamalludin Z., Hizam N.D.A., Liew Y.M., Ung N.M. (2023). Evaluation of intrafractional prostate displacement during prostate radiotherapy using real-time ultrasound system, Physical and Engineering Sciences in Medicine. 46(1), 405-412. doi:10.1007/s13246-023-01230-x
  4. Jalil N.B., Lee P.Y., Nor Afiah M.Z., Abdullah K.L., Azizi F.N.S.M., Rassip N.N.S.A., Ong T.A., Ng C.J., Lee Y.K., Cheong A.T., Razack A.H., Saad M., Alip A., Malek R., Sundram M., Omar S., Sathiyananthan J.R., Kumar P. (2022). Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country, Journal of Cancer Education. 37(1), 169-178. doi:10.1007/s13187-020-01801-6
  5. Lee P.Y., Cheong A.T., Ghazali S.S., Rashid A.A., Ong S.C., Ong S.Y., Alip A., Sylvia M., Chen M.F., Taib N.A., Jaganathan M., Ng C.J., Teo S.-H. (2022). Barriers of and strategies for shared decision-making implementation in the care of metastatic breast cancer: A qualitative study among patients and healthcare professionals in an Asian country, Health Expectations. 25(6), 2837-2850. doi:10.1111/hex.13590
  6. Sum Y.Y., Loh P.Y.J., Jong W.L., Kamarul Zaman Z., Alip A. (2022). PROSPECTIVE OBSERVATIONAL STUDY OF DEEP INSPIRATION BREATH HOLD (DIBH) IN RADIOTHERAPY FOR LEFT-SIDED BREAST CANCER, Journal of Health and Translational Medicine. 25(2), 114-121. doi:10.22452/jummec.vol25no2.18
Others
  1. Cheng ML, See MH, Sinnadurai S, Islam T, Alip A, Ng CG, Taib NA; MyBCC Study Group. Adherence rate and the factors contribute toward the surgical adherence of breast cancer in Malaysia. Breast J. 26(3):568-570. doi: 10.1111/tbj.13617.
  2. Jalil, N.B., Lee, P.Y., Nor Afiah, M.Z. et al. (2020). Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country. J Canc Educ, https://doi.org/10.1007/s13187-020-01801-6
  3. K. Park; J. Vansteenkiste; K.H. Lee; G. Pentheroudakis; C. Zhou; K. Prabhash; T. Seto; P.J. Voon; D.S.W. Tan; J.C.H. Yang; J. Wang; K. Govind Babu; Y. Nakayama; A. Alip; et al (2020). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Ann Oncol (2020) 31:(2) 191 201
  4. Saad, M., Alip, A., Lim, J., Abdullah, M. M., Chong, F., Chua, C. B., Ismail, F., Khong, R. K., Lim, C. S., Loh, C. S., Malek, R., Mohd Ghani, K. A., Md Noor, I., Md Yusoff, N. A., Nasuha, N. A., Razack, A., Soo Hoo, H. F., Sundram, M., Tan, H. M., Thiagarajan, M., The, G. C., Voon, P. J., & Ong, T. A. (2019). Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. BJU international, 124(3), 373 382. https://doi.org/10.1111/bju.14807
  5. Ina Shaliny Duraisamy, MARNIZA SAAD, Adlinda Alip. Single vs multiple fraction palliative radiotherapy for uncomplicated painful bone metastases treated at University of Malaya Medical Centre: A single institutional Malaysian experience. Aging Medicine, 2018;1:133 140.
  6. Lim, I.L., Loo, A.V.P., Subrayan, V., Khang, T.F., See, M.H., Alip, A., Taib, N.A.M. (2018). Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy. The Breast, 39, 117 122.
  7. MARNIZA SAAD, Flora Li Tze Chong, Anita Zarina Bustam, Gwo Fuang Ho, Rozita Abdul Malik, Wan Zamaniah Wan Ishak, Vincent Chee Ee Phua, Mastura Md Yusof, Ning Yi Yap, Adlinda Alip. The efficacy and tolerability of scalp cooling in preventing chemotherapy induced alopecia in patients with breast cancer receiving anthracycline and taxane based chemotherapy in an Asian setting. Ind Journal of Cancer, 2018;157-161.
  8. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
  9. Saad M, Chong FL, Bustam AZ, Ho GF, Malik RA, Ishak WZ, et al. The efficacy and tolerability of scalp cooling in preventing chemotherapy induced alopecia in patients with breast cancer receiving anthracycline and taxane based chemotherapy in an Asian setting. Indian J Cancer 2018
  10. Yap, N. Y., Khoo, W. T., Perumal, K., Ng, K. A., Rajandram, R., Alip, A., Saad, M., & Ong, T. A. (2018). Practical updates in medical therapy for advanced and metastatic renal cell carcinoma. Urological Science, 29(3), 120-128.
  11. J Lim, N Shariff, M Saad, A Alip, T Ong, S Lechmiannandan, F Ahmayuddin, A Mathew, FCL Tze (2017). Abiraterone in metastatic castrate resistant prostate cancer: outcome and tolerance in real-world setting. BJUI International Supplement S4: S10-11.
  12. A Wong, LZ Wang, FC Wong, S Ow, K Nesaretnam, A Pang, CS Tan, YW Lim, GF Ho, Y Lee, HL Yap, S Phang, AB Alip, KY Seng, BC Tai, R Walsh, BC Goh, SC Lee. 2015.Prospective, non-randomised, open-label study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy. European Journal of Cancer 51:S295-S296
  13. Boon Huat Ng, AM Rozita, A Adlinda, Wei Ching Lee, WI Wan Zamaniah. 2015. Extended Field Radiotherapy With or Without Chemotherapy in Patients with Cervical Cancer and Positive Para-Aortic Lymph Nodes: a Single Institution Retrospective Review. Asian Pac J Cancer Prev, 16(9):3827-3833.
  14. J Lim, N Bhoo-Pathy, A Alip, M SAAD, TA Ong, AHA Razack. The prostate cancer profile in multiethnic Asian men.
  15. Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, MARNIZA SAAD, Adlinda Alip, Wan Zamaniah Wan Ishak. Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
  16. Weng Heng Tang, Adlinda Alip, MARNIZA SAAD, Vincent Chee Ee Phua, Hari Chandran, Yi Hang Tan,Yan Yin Tan, Voon Fong Kua, Mohamed Ibrahim Wahid, Lye Mun Tho. Prognostic Factors in Patients with Non-small Cell Lung Carcinoma and Brain Metastases: a Malaysian Perspective
  17. Yoke Fui Wong, Mastura Md Yusof, Wan Zamaniah Wan Ishak, Adlinda Alip,Vincent Chee Ee Phua Treatment Outcome for Head and Neck Squamous Cell Carcinoma in a Developing Country: University Malaya Medical Centre, Malaysia from 2003-2010 Asian Pac J Cancer Prev 2015, 16(7), 2903-2908
  18. CE Phua, WH Tang, MM Yusof, M SAAD, A Alip, MH See, NA Taib, Risk of Treatment Related Death and Febrile Neutropaenia with First Line Palliative Chemotherapy for De Novo Metastatic Breast Cancer in Clinical Practice in a Middle Resource Country
  19. WI Wan Zamaniah, MY Mastura, CE Phua, A Adlinda, S MARNIZA, AM RozitaDefinitive Concurrent Chemoradiotherapy in Cervical Cancer - a University of Malaya Medical Centre Experience. Asian Pac J Cancer Prev, 15 (20), 8987-8992
Article in Proceeding
  1. J.W. Goldman, B.C. Cho, S. Cheng, C. Zhou, B. Liu, Y. Yao, A. Alip, Y.J. Kim, H.J. Soto, Parra T. Kawamura, O. Hataji, H. Hayashi, B. Zurawski, U. Batra, V. Santos, E. Teixeira, C. Dooms, J. Alatorre-Alexander, N. Girard, A.I. Spira, C. Kim, J.K. Sabari, S. Popat, K. Park, R.E. Sanborn, J.C. Curtin, J. Zhang, X. Luo, X. Lyu, A. Bhattacharya, P. Lorenzini, H. Wortman-Vayn, M. Baig, T. Agrawal, R.E. Knoblauch, A.S. Mansfield (2024). TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC. Volume 19(10) S102-S103.
  2. S.-H. Lee1 B.C. Cho2 H. Hayashi3 E. Felip4 A.I. Spira5 N. Girard6,7 Y.J. Kim8 Y. Ostapenko9 P. Danchaivijitr10 B. Liu11 A. Alip12 E. Korbenfeld13 J. Mourão Dias14 K.H. Lee15 H. Xiong16 S.H. How17 Y. Cheng18 G.-C. Chang19 J.C.-H. Yang20 B. Besse21 M. Thomas22,23 J.C. Curtin24 J. Zhang24 J. Xie25 T. Sun25 M. Martinez25 S. Sethi24 R.E. Knoblauch24 E. Fennema26 M. Daksh25 M. Ennis24 J.M. Bauml24 S. Lu27 (2024). Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA. Volume 19(10), Supplement S12.
  3. Byoung Chul Cho, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jong-seok Lee, Se-Hoon Lee, Yuriy Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Tao Sun, Melissa Martinez, Joshua M. Bauml, S. Martin Shreeve, Seema Sethi, Roland E. Knoblauch, Hidetoshi Hayashi, Shun Lu (2023).Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial.
  4. Shun Lu, Byoung Chul Cho, Jong-Seok Lee, Se-Hoon Lee, Pongwut Danchaivijitr,5 Baogang Liu, Adlinda Alip, Hailin Xiong, Soon Hin How, Gee-Chen Chang, James Chih-Hsin Yang, Hiroshige Yoshioka, Mehmet Ali endur, Vijay M. Patil, Koichi Azuma,15 Karen Xia,16 Melissa Martinez,17 Joshua M. Bauml,16 Seema Sethi,16 Hidetoshi Hayashi (2023). Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis.
  5. J Lim, N Shariff, M SAAD, A Alip, T Ong, S Lechmiannandan, F Ahmayuddin, A Mathew, FCL Tze (2017). Abiraterone in metastatic castrate resistant prostate cancer: outcome and tolerance in real-world setting. BJUI International Supplement S4: S10-11.
  6. JY-Y Khoo, A Alip, M SAAD, TA Ong. Treatment outcomes of patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC) on first line docetaxel chemotherapy at University Malaya Medical Centre. BJUI Nov 2016, 118, Supplement 3, 1-19.
  7. N Shariff. (2016, Nov). Diagnostic Dilemma: A case of Metastatic Tubulocystic Carcinoma of the Kidney. Paper presented at European Society of Medical Oncologist Asia Congress, Singapore.
  8. P Yelgambaram. (2016, December) THE TREATMENT OUTCOME OF METASTATIC PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY IN UMMC. Paper presented at European Society of Medical Oncologist Asia, Singapore.
  9. S Nisha, AS Syadwa,S Patricia, S Kisha, MJ Chan, TA Ong, S MARNIZA, A Adlinda. Real-World experience with abiraterone in metastatic castrate resistant prostate carcinoma in University Malaya Medical Centre. BJUI 2016, 118, Supplement 3, 1-19.
  10. SN Masyitah, AHA Razack, TA Ong, M SAAD, A Alip. The unusual kid on the block:Primary Renal Ewing Sarcoma. BJUI Nov 2016, 118, Supplement 3, 1-19.
  11. NK Abd Ghafar, A Alip, TA Ong, M Saad. 2015. Efficacy and safety of first line sunitinib in patients with metastatic renal cell cancer: a Malaysian experience from a single tertiary centre.BJU International 2015, 116, Supplement 4, 1-27.
  12. A.G. Bradshaw, C. Esler, A.E.F. Roy, E. Toy (A Alip), J.F. Lester, J. Kinsman, P. Atherton, C. Knox, G.A. Walker, M.Q. Hatton. Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for NSCLC: experience from nine UK centres.
  13. Nirmala Bhoo-Pathy, Vincent Chee-Ee Phua, Nanthini Thevi Bhoo-Pathy, Gie-Hooi Tan, Adlinda Alip, Mee-Hong See, Suniza Jamaris, Cheng-Har Yip, Nur Aishah Taib. Postmastectomy radiotherapy is not associated with a survival advantage in breast cancer patients with low axillary nodal burden
  14. Mastura Md Yusof, Suhana Yusak, Wan Zamaniah Wan Ishak,, Rozita Abdul Malik, Adlinda Alip, Vincent Phua Chee Ee, Marniza Saad.Outcome of Routine Radioiodine Ablation for Differentiated Thyroid Cancer in an Academic Institution in Kuala Lumpur, Malaysia
  15. Mastura Md Yusof, Wei Ching Lee, Fen Nee Lau, Wan Zamaniah Wan Ishak, Rozita Abdul Malik, Adlinda Alip, MARNIZA SAAD, Vincent Phua Chee Ee. Treatment Outcome of Preoperative Pelvic Chemoradiation for Rectal Carcinoma in a Middle Income Country
  16. Adlinda Alip & Elizabeth Toy. 2011. Continuous hyperfractionated accelerated radiotherapy (CHART) for patients with inoperable non-small cell lung Cancer( NSCLC): 10 year experience of the Exeter Oncology Centre. Lung Cancer, Vol 71,Suppl 1, S35
  17. Jim Lester, Tathagata Das, Claire Esler, J Branagan, Amy Roy, Liz Toy, Adlinda Alip, Jason Lester, Ruth Williams, Matthew Hatton. Treatment with continuous, hyperfractionated, accelerated radiotherapy (CHART) for non-small cell lung cancer (NSCLC): experience from five UK centres between 2005-2010.
  18. A Nassar, A Alip, A Bond and D Hwang. Rate of febrile neutropenia in breast cancer patients receiving adjuvant chemotherapy with FEC and Taxotere.
  19. Jenny Forrest, Francis Daniel, Adlinda Alip, Sam Pillay. Chemotherapy for Metastatic Colorectal Carcinoma between 1st April 2006 and 31st March 2007 according to NICE Guidelines.

RESEARCH PROJECT

National
  1. 2020 - 2023, RU Geran - Fakulti Program
    Clinical And Molecular Investigation On The Role Of Cholesterol In Improving Drug Response In Bladder Cancer ( Co-Researcher)
  2. 2020 - 2023, Fundamental Research Grant Scheme (FRGS)
    Understanding Pattern Of Prostate Motion Through Real-time Tracking For Optimizing Duration-dependent Radiotherapy Treatment Margins ( Co-Researcher)
  3. 2017 - 2019, Prototype Research Grant Scheme (PRGS)
    Multidisciplinary Point of Care Data Capture for Innovative Healthcare: The I-pesakit Breast Cancer Module Prototype, enhancement of the University Malaya Medical Centre I-pesakit Electronic Medical Records ( Co-Researcher)
  4. 2015 - 2017, Geran Penyelidikan Universiti Malaya (UMRG) - AFR (Frontier Science)
    Differentiation between recurrence and radiation necrosis post treatment of glioma. ( Co-Researcher)
  5. 2022 - 2031, Merck Sharpe & Dohme (Malaysia) Sdn Bhd
    A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022) ( Co-Researcher)
  6. 2021 - 2030, Novartis Corporation (Malaysia) Sdn Bhd
    EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combina-tion with trastuzumab and pertuzmab as maintenance therapy in patients with HER2- positive advanced breast cancer with PIK3CA mutation ( Co-Researcher)
  7. 2022 - 2030, Merck Sharpe & Dohme (Malaysia) Sdn Bhd
    Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC ( Co-Researcher)
  8. 2024 - 2030, Astrazeneca Sdn Bhd
    A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF NEOADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) PLUS DURVALUMAB FOLLOWED BY ADJUVANT DURVALUMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED TRIPLE-NEGATIVE OR HORMONE RECEPTOR-LOW/HER2-NEGATIVE BREAST CANCER (D926QC00001; TROPION-BREAST04) ( Principal Investigator(PI))
  9. 2021 - 2026, Merck Sharp & Dohme (M) Sdn. Bhd.
    A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304) ( Co-Researcher)
  10. 2021 - 2026, Arcus Biosciences, Inc.
    A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer ( Co-Researcher)
  11. 2020 - 2026, Johnson & Johnson Sdn. Bhd.
    A Phase 3, Randomized study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. ( Principal Investigator(PI))
  12. 2020 - 2025, AstraZeneca Sdn. Bhd.
    A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA) ( Principal Investigator(PI))
  13. 2018 - 2020, Cancer Research Malaysia
    Metastatic breast cancer decision aids ( Consultant)
  14. 2015 - 2017, Private Funding
    MONALEESA 7 BREAST CANCER STUDY ( Principal Investigator(PI))
  15. 2013 - 2015, NONE
    Phase II randomized study of docetaxel with or without low-dose, short course sunitinib in the treatment of advanced solid tumors. ( Consultant)
  16. 2013 - 2015, NONE
    Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer ( Consultant)
  17. 2014 - 2015, Nova Satra Health
    Studies of Epigenetic Changes in Circulating Tumor Cells in Breast Cancer ( Consultant)
Private
  1. 2023 - 2029, Roche (Malaysia) Sdn. Bhd.
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER ( Co-Researcher)
  2. 2024 - 2029, GILEAD SCIENCES, INC.
    A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+)/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2) (HER2 IHC0 OR HER2-LOW [IHC 1+, IHC 2+/ISH]) INOPERABLE, LOCALLY ADVANCED, OR METASTATIC BREAST CANCER AND HAVE RECEIVED ENDOCRINE THERAPY ( Principal Investigator(PI))
  3. 2023 - 2028, Exelixis, Inc.
    A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF XL092 + NIVOLUMAB VS SUNITINIB IN SUBJECTS WITH ADVANCED OR METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA ( Co-Researcher)
  4. 2024 - 2028, OLEMA PHARMACEUTICALS, INC.
    A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK4/6 INHIBITOR THERAPY (OPERA-01) ( Co-Researcher)
  5. 2023 - 2027, Gilead Sciences, Inc.
    A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN S CHOICE IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHOSE TUMORS DO NOT EXPRESS PD-L1 OR IN PATIENTS PREVIOUSLY TREATED WITH ANTI-PD-(L)1 AGENTS IN THE EARLY SETTING WHOSE TUMORS DO EXPRESS PD-L1 ( Principal Investigator(PI))
  6. 2023 - 2027, Gilead Sciences, Inc.
    A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN AND PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIANS CHOICE AND PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER, WHOSE TUMORS EXPRESS PD-L1 ( Principal Investigator(PI))
  7. 2020 - 2026, Johnson & Johnson Sdn. Bhd.
    A Phase 3, Randomized study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. ( Principal Investigator(PI))
  8. 2023 - 2026, Astrazeneca Sdn. Bhd.
    A PHASE I/II, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF AZD2936 ANTI-TIGIT/ANTI-PD-1 BISPECIFIC ANTIBODY IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (ARTEMIDE-01) ( Co-Researcher)
  9. 2024 - 2025, Hexal AG
    A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO COMPARE PHARMACOKINETICS OF GME751 (PROPOSED PEMBROLIZUMAB BIOSIMILAR) AND US-LICENSED AND EUAUTHORIZED KEYTRUDA IN PARTICIPANTS WITH STAGE II AND III MELANOMA REQUIRING ADJUVANT TREATMENT WITH PEMBROLIZUMAB ( Co-Researcher)
  10. 2023 - 2025, Private Funding
    Dosimetric And Treatment Plan Assessment Of Stereotactic Radiosurgery And Stereotactic Body Radiotherapy In Malaysia ( Co-Researcher)
  11. 2020 - 2024, MSD Grant
    A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671), University Malaya Medical Centre (UMMC) (Pusat Perubatan Universiti Malaya)(PPUM) ( Co-Researcher)
  12. 2018 - 2022, Merck Sharp & Dohme (M) Sdn. Bhd.
    A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676) ( Principal Investigator(PI))
International
  1. 2021 - 2036, Private Funding
    A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PAPILLON) ( Principal Investigator(PI))
  2. 2021 - 2036, Private Funding
    AMPLITUDE: A Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Metastatic Prostate Cancer with Certain Genetic Changes ( Consultant)
  3. 2020 - 2035, Private Funding
    EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess safety and efficacy of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation ( Principal Investigator(PI))
  4. 2022 - 2034, F. Hoffman-La Roche Ltd
    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotheraphy In Patients With Estrogen Receptor-Positive HER2-Negative Early Breast Cancer ( Co-Researcher)
  5. 2023 - 2026, Japan Study Group of Prostate Cancer
    Research concerning Background Factors at Time of Diagnosis and Initial Treatment and Treatment Progress of Prostate Cancer Patients: Asia Multi-institution Joint Study (Asia Study Group of Prostate Cancer; A-CaP Study) ( Co-Researcher)
  6. 2023 - 2026, University College London
    ARCHERY: ARTIFICIAL INTELLIGENCE BASED RADIOTHERAPY TREATMENT PLANNING FOR CERVICAL AND HEAD AND NECK CANCER ( Co-Researcher)
  7. 2020 - 2025, Private Funding
    A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer ( Principal Investigator(PI))
  8. 2022 - 2025, National Cancer Centre Japan
    ATLAS Project, National Cancer Centre, Tokyo ( Co-Researcher)
  9. 2019 - 2024, Merck Sharp & Dohme (M) Sdn. Bhd
    KEYNOTE-676 : Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676) ( Principal Investigator(PI))
  10. 2019 - 2024, celltrion
    A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer ( Principal Investigator(PI))
  11. 2019 - 2024, Private Funding
    A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer ( Principal Investigator(PI))
  12. 2020 - 2024, Johnson & Johnson
    PREVALENCE : A biomarker study to determine frequency of DNA-repair defects in men with metastatic prostate cancer. ( Consultant)
  13. 2023 - 2024, National institutes of health, NCI, MRC via UK Research and UKRI
    ARCHERY: a prospective observational study of artificial intelligence-based radiotherapy treatment planning for cervical, head and neck and prostate cancer, University College Hospital London ( Co-Researcher)
  14. 2019 - 2023, Celltrion, Inc.
    A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer ( Principal Investigator(PI))
  15. 2020 - 2023, Merck Sharp & Dohme (M) Sdn. Bhd
    KEYNOTE-992 : A Phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy (CRT) versus CRT alone in muscle-invasive bladder cancer. KEYNOTE-992 ( Consultant)
  16. 2018 - 2022, syneos health
    A Phase 1, Open-Label, Dose Escalation And Expansion Study Of Pf-06801591 In Patients With Locally Advanced Or Metastatic Melanoma, Squamous Cell Head And Neck Cancer, Ovarian Cancer, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma Or Other Solid Tumors. ( Consultant)
  17. 2019 - 2022, Johnson&Johnson
    MAGNITUDE Study : A phase 3 randomized, placebo-controlled, double-blind study of niraparib in combination with abiraterone acetate and prednisolone versus abiraterone acetate and prednisolone for treatment of subjects with metastatic prostate cancer. ( Consultant)
  18. 2014 - 2021, AB Science S.A.
    A prospective, multicenter, randomized, double-blind, placebo controlled, 2 parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC) ( Principal Investigator(PI))
  19. 2015 - 2020, Industry
    KEYNOTE-052 : A Phase 2 Clinical Trial of Pembrolizumab in Subjects with advanced/ unresectable or metastatic urothelial cancer. ( Consultant)
  20. 2012 - 2018, Janssen Cilag
    LATITUDE : A randomised double-blind comparative study of Zytiga (abiraterone acetate) plus low dose prednisolone plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed subjects with high risk metastatic hormone-naive prostate cancer (mHNPC). LATITUDE ( Consultant)
  21. 2013 - 2018, Medivation and Astella
    PROSPER A multinational, Phase 3, Randomized, Double blinde, Placebo controlled, Efficacy and Safety of Enzalutamide in Patient With Nonmetastatic Castration-Resistant Prostate Canncer ( Principal Investigator(PI))
  22. 2014 - 2018, AB Science
    A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC) ( Principal Investigator(PI))
  23. 2015 - 2018, MSD
    A randomised open label phase 3 study of single agent pembrolizumab vs single agent chemo per physician's choice for metastatic triple negative breast cancer-[KEYNOTE-119 study] ( Consultant)
  24. 2013 - 2016, Novartis Corporation (Malaysia) Sdn Bhd
    CRAD001Y2201 (BOLERO-6) A three-arm, randomized, open label, phase II study of everolimus in combination with exemestan eversus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole. ( Principal Investigator(PI))
  25. 2014 - 2015, Genetech Inc
    GDC-0068 Study (JAGUAR) A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, An Inhibitor to Akt, In Combination with Fluoropyrimidine plus Oxaliplatin in Patients with Locally Advanced or Mestatatic Gastric or Gastroesophageal Junction Adenocarcinoma ( Consultant)
  26. 2014 - 2015, NUS
    A Prospective Cohort Study of Patients with Malignant Cord Compression ( Consultant)

CONSULTANCY PROJECT

  • B.I Oncology Advisory Group Meeting, Boehringer Ingelheim in Malaysia , Consultant
    23 Aug 2021 - 23 Aug 2021 (National)
  • B.I Oncology Advisory Group Meeting, Boehringer Ingelheim, Consultant
    23 Aug 2021 - 23 Aug 2021 (National)
  • Agenda for Cipla and Mos (Malaysia Oncology Society) Joined Talk On Pegfilgrastim and Abiraterone., CIPLA MALAYSIA, Consultant
    09 Jul 2021 - 09 Jul 2021 (National)
  • Agenda for Cipla and Mos (Malaysia Oncology Society) Joined Talk On Pegfilgrastim and Abiraterone., Cipla Malaysia Sdn Bhd, Consultant
    09 Jul 2021 - 09 Jul 2021 (National)
  • Virtual Meeting of Advisory Board Meeting On Renal Cell Carcinoma (Rcc Abm), Eisai Malaysia Unit 701D, Consultant
    08 May 2021 - 08 May 2021 (National)
  • Virtual Meeting of Advisory Board Meeting On Renal Cell Carcinoma (Rcc Abm), Eisai Malaysia , Consultant
    08 May 2021 - 08 May 2021 (National)
  • Ipsen Malaysia Renal Cell Carcinoma Advisory Board Meeting, Ipsen Pharma, Consultant
    01 Apr 2021 - 01 Apr 2021 (International)
  • Ipsen Malaysia Renal Cell Carcinoma Advisory Board Meeting, Ipsen Pharma Singapore
    01 Apr 2021 - 01 Apr 2021 (International)
  • Development of Guidelines for Centre of Excellence (5 Service Standards) in Malaysia: Mhtc Projec, malaysian society for quality in health, Consultant
    24 Mar 2021 - 24 Mar 2021 (National)
  • Development of Guidelines for Centre of Excellence (5 Service Standards) in Malaysia: Mhtc Project, malaysian society for quality in health
    01 Mar 2021 - 01 Mar 2021 (National)
  • Msd Malaysia Rcc Cancer Expert Input Forum, MSD
    01 Jan 2020 - 01 Jan 2020 (National)
  • Virtual Expert Input Forum Meeting On Lung Cancer, MSD
    01 Jan 2020 - 01 Jan 2020 (National)
  • Unfolding The Management Paradigm of Locally Advanced Nsclc: is The Unmet Fulfilled, AstraZenec Sdn Bhd
    01 Aug 2019 - 01 Aug 2019 (National)
  • 2nd Cinv Panel Netork Asia- Bangkok, Helsinn Healthcare SA
    01 May 2019 - 01 May 2019 (International)
  • First Line Nsclc Advisory Meeting, Boehringer Ingelheim (M) Sdn Bhd
    01 Mar 2019 - 01 Mar 2019 (National)
  • Breast Cancer Advisory Board, Pfizer (Malaysia) Sdn Bhd
    01 Jan 2019 - 01 Jan 2019 (National)
  • Apalutamide Advisory Board, Johnson & Johnson Sdn Bhd
    01 Jan 2019 - 01 Jan 2019 (National)
  • Amy-Asg Joint Prostate Cancer Medical Advisory Board Meeting, Astellas Pharma Malaysia Sdn Bhd
    01 Nov 2018 - 01 Nov 2018 (International)
  • Pan-Asia Adapted Esmo Consensus Guidelines for The Management of Patients With Metastatic Non-Small Cell Lung Cancer, ESMO
    01 Oct 2018 - 01 Oct 2018 (International)
  • 2nd Expanded Asia Nsclc Advisory Board Meeting, Boehringer Ingelheim
    01 Oct 2018 - 01 Oct 2018 (International)
  • 2nd Advanced Lung Cancer Academia, Boehringer Ingelheim
    01 Sep 2018 - 01 Sep 2018 (International)
  • Sea Prostate Cancer Core Faculty Meeting, Johnson & Johnson Sdn. Bhd
    01 Sep 2018 - 01 Sep 2018 (National)
  • Advisory Board Meeting- Clinical Management of Lenvima in The Treatment of Metastatic Renal Cell Carcinoma, Eisai (M) Snd Bhd
    01 Jan 2018 - 01 Jan 2018 (National)
  • Malaysia Nsclc Advisory Board Meeting, Novartis
    01 Dec 2017 - 01 Dec 2017 (National)
  • Expanded Asia Nsclc Advisory Board Meeting, Boehringer Ingelheim
    01 Dec 2017 - 01 Dec 2017 (International)
  • Seask Nsclc Adboard for Oncologists, Boehringer Ingelheim (Malaysia)
    01 Aug 2017 - 01 Aug 2017 (National)
  • Seask Nsclc Adboard for Oncologists, Boehringer Ingelheim (Malaysia)
    01 Jan 2017 - 01 Jan 2017 (International)
  • Prostate Cancer: Updates On Management, Abbvie Malaysia
    01 Dec 2016 - 01 Dec 2016 (National)
  • Targeting The Cdk 4/6 Pathway in Treating Hr+/Her2- Metastatic Breast Cancer., PFIZER (MALAYSIA) SDN BHD
    01 Dec 2016 - 01 Dec 2016 (National)
  • Scientific Presenter At Advanced Lung Cancer Academia, Boehringer Ingelheim
    01 Sep 2016 - 01 Sep 2016 (National)
  • Cme Meeting On Brains Mets in Alk Positive Patient On Xalkori as First Line, Pfizer (Malaysia) Sdn Bhd
    01 Aug 2016 - 01 Aug 2016 (National)
  • Review Treatment Guidelines in Advance Nsclc, Eli Lily Malaysia Sdn Bhd
    01 Aug 2016 - 01 Aug 2016 (National)
  • Healthcare Professional Service, AbbVie Sdn Bhd
    01 Aug 2016 - 01 Aug 2016 (National)
  • Medical Reviewer for Transperfect Translation, Transperfect Translation
    01 Dec 2013 - 01 Dec 2015 (International)
  • Internal Training for Orient Europharam On Breast and Lung Cancer and Treatment Algorithm., Orient Europharma
    01 Jun 2015 - 01 Jun 2015 (National)
  • Pfizer Singapore-Malaysia Advisory Board Meeting On Optimal Management of Renal Cell Cancer, Pfizer
    01 Jun 2015 - 01 Jun 2015 (National)
  • Decision Aid for Localised Prostate Cancer, University of Malaya and University Putra Malaysia
    01 Jun 2014 - 01 Jun 2015 (National)
  • Kol Trainer Focusing On Metastatic Castrate Resistant Prostate Cancer for Johnson and Johnson, Janssen (Johnson and Johnson) Malaysia
    01 Jun 2015 - 01 Jun 2015 (National)
  • Prostate Cancer Asia / Oceania Advisory Board Meeting, Astella Pharma
    01 Apr 2015 - 01 Apr 2015 (International)
  • Everolimus Round Table Discussion, Novartis Oncology
    01 Apr 2015 - 01 Apr 2015 (National)
  • Astella: Prostate Advisory Board Meeting, Astella Pharma Singapore
    01 Jan 2015 - 01 Jan 2015 (International)
  • Committee for Antibiotics Guidelines for Ummc 2013, university of malaya medical centre
    01 Dec 2013 - 01 Dec 2014 (National)
  • Advance Breast Cancer Advisory Board Meeting, Novartis
    01 Dec 2014 - 01 Dec 2014 (National)
  • Metastatic Castrate Resistant Prostate Cancer Expert Panel Meeting, Astella Pharma Singapore
    01 Dec 2014 - 01 Dec 2014 (International)
  • Apsa Breast Cancer Advisory Board Meeting, Novartis Coorperation Malaysia Sdn Bhd
    01 Dec 2014 - 01 Dec 2014 (International)
  • Revision of National Chemotherapy Protocol 2014, Ministry of Health
    01 Dec 2014 - 01 Dec 2014 (National)
  • 3nd Xarelto Advisory Board Meeting- Vte Treatment, Bayer Healthcare Pharmaceutical
    01 Dec 2013 - 01 Dec 2013 (National)
  • Gsk Asia Pacific Renal Cell Carcinoma Votrient Advisory Board Meeting, GlaxoSmithKline Oncology
    01 Jun 2013 - 01 Jun 2013 (International)

PAPER PRESENTED

PLENARY SPEAKER
  1. Immuno Oncology: New in Cancer Treatment , ICONIC EDUCATIONAL PROGRAM, , Astrazeneca  (National) (11 Mar 2018 - 11 Mar 2018)
INVITED SPEAKER
  1. Will Oncology Become the Domain for Early-Stage Lung Cancer?, 32nd Annual Congress of the Association of Thoracic and CV Surgeons of Asia ATCSA, ATCSA (International) (22 Nov 2024 - 24 Nov 2024)
  2. Adjuvant therapy for Renal Cell Cancer: Where Do we Now Stand?, 35th ASCOMOS Penang 2024, Malaysian Oncological Society (International) (11 Oct 2024 - 13 Oct 2024)
  3. Understanding DUAL IO, DUAL-IO Advisory Board Meeting , BMS (National) (21 Nov 2022 - 21 Nov 2022)
  4. Review: updates on the new systemic treatment options in 1L advanced RCC, Dual IO Advisory Board Meeting, BMS (National) (21 Nov 2022 - 21 Nov 2022)
  5. Adjuvant Therapy in Stage 1 NSCLC, Reconnecting for Our Future in Cancer Care, MOS (International) (05 Nov 2022 - 05 Nov 2022)
  6. Management of Stage III Lung Cancer, Lung Cancer Workshop, UMMC (University) (29 Oct 2022 - 29 Oct 2022)
  7. Role of Radiotherapy in Lung Cancer, Lung Cancer Workshop, UMMC (University) (29 Oct 2022 - 29 Oct 2022)
  8. How I Manage Stage III Lung Cancer, Malaysian Thoracic Society Annual Congress (MTS Congress 2022), MTS (National) (14 Oct 2022 - 16 Oct 2022)
  9. Unmet Need in Immuno-oncology, Malaysian Thoracic Society Annual Congress (MTS Congress 2022), MTS (National) (13 Oct 2022 - 16 Oct 2022)
  10. What s new in First Line Renal Cell Cancer, Congress Highlight ASCO GU 2022, IPSEN (International) (10 Mar 2022 - 10 Mar 2022)
  11. A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1., Best of ASCO 2021 Annual Meeting, ASCO, MOS (International) (31 Jul 2021 - 01 Aug 2021)
  12. CASE DISCUSSION 2: LUNG CANCER , PACIFIC MDT CASE FORUM, Astrazeneca  (University) (26 Apr 2021 - 26 Apr 2021)
  13. Mini Specializing Opportunities, MMI into the Future 2.0, MMI Malaysia (National) (13 Dec 2020 - 13 Dec 2020)
  14. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis., ASCO20 Virtual Conference, MCIgets India (International) (05 Dec 2020 - 06 Dec 2020)
  15. The Importance of Uro-Oncology Collaboration in the Management of Advanced RCC, Malaysian Urological Conference (MUC) 2020, Malaysian Urological Association (National) (27 Nov 2020 - 27 Nov 2020)
  16. Lung Cancer Update, Southern Lung Cancer Update, Radiotherapy & Oncology HSI Johor (National) (04 May 2019 - 04 May 2019)
  17. Cancer Cachexia CINV, 2nd CINV Panel Netork Asia- Bangkok, Mundipharma  (International) (27 Apr 2019 - 28 Apr 2019)
  18. Managing Metastatic Hormone Sensitive Prostate Cancer (mHSPC), The Multidisciplinary Team in Prostate Cancer Management (MDT-PaCMan), Jansen and Jansen (National) (06 Apr 2019 - 06 Apr 2019)
  19. From mHSPC to mCRPC- Navigating the Advanced Prostate Cancer Landscape , MDT-PaCMan 1.0 The Multidisciplinary Team in Prostate Cancer Management, Johnson and Johnson (National) (06 Apr 2019 - 06 Apr 2019)
  20. Case discussion of patients going through sequential approach (Afatinib Osimertinib), 1st NSCLC Advisory Board Meeting , Boehringer Ingelheim  (National) (23 Mar 2019 - 23 Mar 2019)
  21. Intergrating CDK4/5 Inhibitor in the MAnagement of ER+HER2-mBC patients, CME: Intergrating CDK4/5 Inhibitor in the MAnagement of ER+HER2-mBC patients, Pfizer Malaysia Sdn Bhd (National) (28 Feb 2019 - 28 Feb 2019)
  22. Evolving Option in the Management of Lung Cancer , CME TALK, University Malaya Specialist Centre (UMSC) (National) (23 Feb 2019 - 23 Feb 2019)
  23. Lung SBRT, The 3rd International Clinical Oncology Congress (Congress), ISCO (International) (19 Dec 2018 - 22 Dec 2018)
  24. Breast SBRT, The 3rd International Clinical Oncology Congress (Congress), ISCO (International) (19 Dec 2018 - 22 Dec 2018)
  25. Lung Radiotherapy, The 3rd International Clinical Oncology Congress, ISCO (International) (19 Dec 2018 - 22 Dec 2018)
  26. Is sequencing TKIs a Viable Strategy to Prolong Survival in EGFR M+ Patients: An Asian Perspective, Onco Symposium 2018, Boehringer Ingelheim (National) (07 Dec 2018 - 07 Dec 2018)
  27. Current standards and practice changing studies in ER positive advanced/metastatic Breast Cancer, The Fifth Edition Of "MERCK AFRICA ASIA LUMINARY", Merck Foundation (International) (30 Oct 2018 - 31 Oct 2018)
  28. Advances in the management of m0CRPC and mCRPC, ADVISORY BOARD: Advances in the management of m0CRPC and mCRPC , Astellas (International) (27 Oct 2018 - 27 Oct 2018)
  29. Advanced Lung Cancer, 2nd Advanced Lung Cancer Academia, Boehringer Ingelheim (National) (28 Apr 2018 - 28 Apr 2018)
  30. Resistance Pathway to Targeted Therapy, Precision Medicine: A Way Forward, IKN (National) (04 Sep 2017 - 06 Dec 2017)
  31. Biological basis of combining Radiotherapy with Immunotherapy, Precision Medicine: A way forward, IKN (National) (04 Sep 2017 - 06 Sep 2017)
  32. Neoadjuvant Chemotherapy For Breast Cancer, Johor Oncology Meeting, Pusat Rawatan Onkologi, HSI (National) (03 Aug 2017 - 05 Aug 2017)
  33. Medical Management in Renal Cell Carcinoma, 3rd Johor Oncology Meeting, Pusat Rawatan Onkologi, JB (National) (03 Aug 2017 - 05 Aug 2017)
  34. Hormonal Therapy for Prostate Cancer, Seminar Kanser Prostat, HSI, Johor Bahru (Others) (22 Apr 2017 - 22 Apr 2017)
  35. Chemotherapy for Prostate Cancer, Seminar for Prostate Cancer 2017, HSI, HSA, Johor Bahru (Others) (22 Apr 2017 - 22 Apr 2017)
  36. Management of adverse events from TKIs, Annual Scientific Conference of the Malaysian Oncological Society, Malaysian Oncological Society (National) (10 Nov 2016 - 10 Nov 2016)
  37. Chemohormonal Approach-Relevance and Challenges in local setting: Oncologist views, Art Of Oncology, Sanofi (National) (17 Sep 2016 - 18 Sep 2016)
  38. ADT and Novel Agents in Hormone-Sensitive Prostate Cancer, 3i Pathways Workshop, Menarini (National) (13 Aug 2016 - 13 Aug 2016)
  39. Brain Metastases in ALK-positive patient on Xalkori as first line, Oncology CME meeting, Pfizer (Others) (21 Apr 2016 - 21 Apr 2016)
  40. Case study: progression following chemotherapy, Art of Oncology 2015, Sanofi Malaysia (National) (13 Sep 2015 - 13 Sep 2015)
  41. Multidisciplinary Management of Solid Tumors How Can We Improve Outcomes?, Asia-Pacific Oncology Conference Sanofi Oncology 11-12th July 2015 , Sanofi (International) (12 Jul 2015 - 12 Jul 2015)
  42. Past, present and future of Prostate Cancer Treatment- Case Studies, GP Seminar on Prostate Cancer, Janssen Malaysia (National) (13 Jun 2015 - 13 Jun 2015)
  43. Targeted Therapy, Oncology Nursing Preceptorship Program, Roche Myanmar/UMMC (International) (13 Apr 2015 - 15 Apr 2015)
  44. Capecitabine in Metastatic Breast Cancer and Case Studies, Capecitabine Preceptorship Program, Roche/UMMC (International) (06 Apr 2015 - 08 Apr 2015)
  45. Radiotherapy in Prostate Cancer, Prostate Cancer Symposium, The Brunei Cancer Centre (International) (15 Feb 2015 - 15 Feb 2015)
  46. CASE STUDY : How Do We Treat Low Risk Elderly vs High Risk Young Patients with Prostate Cancer Today?, HIGHLIGHTS OF ESMO 2014 CONGRESS SOUTH-EAST ASIA SUMMIT , Malaysian Oncological Society (International) (23 Jan 2015 - 25 Jan 2015)
  47. Challenging cases in mCRPC: Chemotherapy, Art Of Oncology Meeting, Sanofi Oncology, Malaysian Oncological Society and Malaysian Urological Association (National) (06 Dec 2014 - 06 Dec 2014)
  48. ADT and Novel Agents in Hormone Sensitive Prostate Cancer, 23rd Malaysian Urological Conference, Ministry of Health Malaysia, Malaysian Urological Association (National) (21 Nov 2014 - 21 Nov 2014)
  49. Metastatic RCC: Making The Right Choice:First Line Treatment : Comparing Efficacy, Safety & Tolerability, URo-Oncology Forum, Malaysian Urological Association (National) (07 Jun 2014 - 08 Jun 2014)
  50. Best Practice Sharing-Uro Onco Joint Managment of mRCC, Pfizer Oncology Workshop:Winning Oncology Ways, Pfizer Oncology (International) (25 Feb 2014 - 25 Feb 2014)
  51. Metastatic Renal Cell Cancer Treatment: A choice and the choice, Pfizer Oncology Workshop:Winning Oncology Ways , Pfizer Oncology (International) (25 Feb 2014 - 25 Feb 2014)
  52. Review of bladder cancer treatment., Annual Scientific Congress of Malaysian Oncological Society 2013, Malaysian Oncological Society (International) (29 Nov 2013 - 01 Dec 2013)
  53. Impact of Radiotherapy following primary tumour extirpation on survival of women with De novo stage 4 breast cancer, Research Meeting 2013, KL Malaysia (International) (28 Oct 2013 - 29 Oct 2013)
  54. Adjuvant Therapy in Soft Tissue Sarcoma, 2013 Joint Scientific Meeting Between College of Radiology AMM,Malaysian Oncological Socety and Malaysian Society for Radiolographers, College of Radiology AMM,Malaysian Oncological Socety and Malaysian Society for Radiolographers (National) (15 Jun 2013 - 15 Jun 2013)
  55. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer, 21st Joint Malaysian-Scottish Urological Conference, Malaysian Urological Association, Scottish Urological Society (International) (24 Nov 2012 - 24 Nov 2012)
  56. Changing Landscape of mCRPC Tailoring therapy to optimise treatment outcomes, Art of Oncology The Malaysia-Singapore Pharmacists Forum (International) (20 Oct 2012 - 20 Oct 2012)
  57. Principle of Chemotherapy and Radiotherapy, Orthopaedic Oncology Course, Oncology Unit of Department of Orthopaedic Surgery, University of Malaya Medical Centre (National) (13 Oct 2012 - 13 Oct 2012)
EVENT ORGANISER
  1. Masterclass in Systemic Cancer Therapy 2017, Masterclass in Systemic Cancer Therapy 2017, UM, MOS (National) (04 Mar 2017 - 05 Mar 2017)
  2. Stereotactic Radiosurgery/Radiotherapy Workshop, Stereotactic Radiosurgery/Radiotherapy Workshop, Clinical Oncology Dept, FOM, University of Malaya Medical Centre (National) (25 May 2016 - 27 Jan 2017)
  3. None, Stereotactic Radiosurgery/ Radiotherapy for Cranial Lesions Workshop, UMMC/Brainlab (National) (11 May 2015 - 14 May 2015)
ORAL PRESENTER
  1. Pembrolizumab plus Axitinib vs Sunitinib as first line for advanced RCC. Analysis of progression after first subsequent therapy, Best Of ASCO 2022, ASCO (International) (23 Jul 2022 - 24 Jul 2022)
POSTER PRESENTER
  1. Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer, THE IASLC 19TH WORLD CONFERENCE ON LUNG CANCER , IASLC (International) (23 Sep 2018 - 26 Sep 2018)
  2. Efficacy and Safety of Pazopanib in Advanced Renal Cell Cancer: Review in UMMC, ASCOMOS 29th MOS Scientific Congress 2017, Malaysian Oncological Society (National) (08 Dec 2017 - 10 Dec 2017)
  3. The Treatment Outcome of Metastatic Prostate Cancer Patients Treated with Androgen Deprivation Therapy in UMMC., ESMO Asia 2016, ESMO (International) (16 Dec 2016 - 19 Dec 2016)
  4. Diagnostic Dilemma: A case of Metastatic Tubulocystic Carcinoma of the Kidney., ESMO Asia 2016, European Society of Medical Oncologist (International) (16 Dec 2016 - 19 Dec 2016)
PRESENTER
  1. NON CLEAR CELL RCC, Renal Cancer Preceptorship (RECAP), Urology Department (International) (03 May 2018 - 04 May 2018)
  2. FISRT LINE OPTION IN mRCC, Renal Cancer Preceptorship, Urology Department (International) (03 May 2018 - 04 May 2018)
  3. RADIOTHERAPY IN RCC, RCC PRECEPTORSHIP, UNIVERSITY MALAYA (National) (03 May 2018 - 04 May 2018)
  4. Case Discussion-EGFR-positive Lung Cancer, Advanced Lung Cancer Academia, Boehringer Ingelheim (National) (03 Sep 2016 - 03 Sep 2016)
  5. Case presentation: Illustration on optimization of treatment response and patient care management with ceritinib therapy in advanced ALK+ NSCLC patients, Malaysia Ceritinib and ALK+ Non-Small Cell Lung Cancer Advisory Board-"raising the Bar in Treatment of ALK positive NSCLC, Novartis Malaysia (National) (15 Nov 2015 - 15 Nov 2015)
  6. Case studies on metastatic castrate-resistant prostate cancer., Clinical Conversations in mCRPC ; A Practical Approach to Optimizing New Treatment Options, Janssen Pharmaceutical Companies (National) (21 Jun 2014 - 21 Jun 2014)
  7. Management of Prostate Cancer- Case study presentation, Emerging Trends in characterization and treatment decision of metastatic castration resistant prostate caner , Janssen cilag (International) (11 Jul 2013 - 11 Jul 2013)
OTHERS
  1. Advanced Urology Course for Prostate Cancer, Penile Cancer and Testicular Cancer 2019 Date , Advanced Urology Course for Prostate Cancer, Penile Cancer and Testicular Cancer 2019 , (MALAYSIAN UROLOGICAL ASSOCIATION) (National) (23 Mar 2019 - 24 Mar 2019)
  2. Section of URo-Oncology Forum 2018, Section of URo-Oncology Forum 2018, Malaysian urology Society/ Malaysia Oncology Socienty (National) (30 Jun 2018 - 01 Jul 2018)
  3. Strategise Optimal Solution, Section of Uro-Oncology Forum 2016, MOH Malaysia, Malaysian Urological Association and Malaysian Oncological Society (National) (30 Apr 2016 - 30 Apr 2016)
  4. Prognostic Factors in Non-small Cell Lung Carcinoma Patients with Brain Metastases: A Malaysian perspective, 2014 IASLC Asia Pacific Lung Cancer Conference (APLCC), Malaysian Oncological Society and Malaysian Thoracic Society (International) (06 Nov 2014 - 06 Nov 2014)
  5. Radiotherapy Session, Annual Scientific Congress Of Malaysian Oncological Society 2012: Effective Cancer Treatment: Updating Professionals, Educating The Public, Malaysian Oncological Society (National) (07 Sep 2012 - 07 Sep 2012)

ACADEMIC/ PROF. SERVICES

Evaluation
  1. (2024) Umsc Care Fund Research Grant Reviewer, University, (Reviewer)
  2. (2024) Specialty Subcommittee for Education (Ssc-Edu) for Clinical Oncology, Medical Education Committee, Mmc, National, (External Assessor)
  3. (2023) Frgs Evaluator, University, (Internal Evaluator)
  4. (2022) Panel Reviewer for Umsc Ca.R.E Fund Research Grant 2022, University, (Internal Assessor)
  5. (2021) Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer, (CO-PI)
  6. (2020) Developing an intervention decision aid for patients with metastatic breast cancer., (Advisory Committee)
  7. (2019) Review article for publication , (Reviewer)
  8. (2016) The Clinical Utility of Perfusion Imaging in Predicting True Tumour Progression From Treatment Effects of High Grade Gliomas for the 'Asia-Pacific Journal of Clinical Oncology., (Reviewer)
  9. (2015) "Radiotherapy for brainstem gliomas in children and adults: A single-institution experience and literature review" for the Asia-Pacific Journal of Clinical Oncology, (Reviewer)
Contribution to external organisation
  1. (2022) Dual Io Advisory Board Meeting, National, (Expert Advisor)
  2. (2022) Cabonivo and Rcc Advisory Board Meeting, National, (Expert Advisor)
  3. (2022) Malaysian Cabonivo and Renal Cell Cancer Advisory Board Meeting, National, (Expert Advisor)
  4. (2022) Eisai Regional Asia Rcc Advisory Board Meeting, 18th March 2022, International, (Expert Advisor)
  5. (2022) Cdk 4/6 Inhibitors Advisory Board, National, (Expert Advisor)
  6. (2021) Hallmarks of Cancer Course UM 2021, University, (Expert Advisor)
  7. (2021) B.I Oncology Advisory Group Meeting, National, (Expert Advisor)
  8. (2021) Agenda for Cipla and Mos (Malaysia Oncology Society) Joined Talk On Pegfilgrastim and Abiraterone., National, (Expert Advisor)
  9. (2021) Virtual Meeting of Advisory Board Meeting On Renal Cell Carcinoma (Rcc Abm), National, (Expert Advisor)
  10. (2021) Ipsen Malaysia Renal Cell Carcinoma Advisory Board Meeting International, International, (Expert Advisor)
  11. (2021) Development of Guidelines for Centre of Excellence (5 Service Standards) in Malaysia: Mhtc Project, National, (Expert Advisor)
Contribution to event
  1. (2022) Chairperson/Moderator, National, (Panelist/Moderator)
  2. (2022) Dual Immuno-Oncology Meeting, National, (Panelist/Moderator)
  3. (2022) Chairperson for Cns Section On Glioma and Multiple Brain Metastases, International, (Panelist/Moderator)
  4. (2022) Chairwoman, Organining Committee, National, (Event Organiser)
  5. (2022) Panelist, Organising and Scientific Committee for Malaysian Prostate Cancer Consensus, Mypcc 2022, National, (Event Organiser)
  6. (2022) Scientific Committee, National, (Event Organiser)

SUPERVISION

Postgraduate Student
PhD/ Doctoral
  1. (2023) ASSESSING TECHNICAL ASPECTS AND APPLICATIONS OF DEEP INSPIRATION BREATH HOLD (DIBH) METHOD FOR THORACOABDOMINAL RADIOTHERAPY, HOANG ANH TUNG
  2. (2020) Tajuk Penyelidikan: Assessing Technical Aspects And Applications Of Deep Inspiration Breath Hold (Dibh) Method For Thoracoabdominal Radiotherapy, Hoang Ann Tung
Master
  1. (2017) Quality Assesment of Prostate Radiotherapy Using Data Envelopment Analysis, Najihah binti Abu Bakar(A04837)
  2. (2016) Denosumab versus Zoledronic Acid in Preventing Skeletal Related Events(SRE) in patient with bone metastases - A UMMC Experience 2013-2015, Syafirin Abd Sani
  3. (2013) The use of chemotherapy in castrate-resistant prostate cancer in UMMC, Dr Junie Khoo Yu Yen
  4. (2013) The usage of radiotherapy in oncological treatment: retrospective studies comparing two main university hospitals in Malaysia, Dr Marfuah Nik Eezamuddeen
  5. (2013) The perception of alternative medicine among health professionals and patients, Dr Tan Chih Kiang
  6. (2013) Management and outcome of Germ Cell tumour in University of Malaya Medical Centre, Dr Choong Swee Hsia
  7. (2013) Efficacy and safety of denosumab in Giant Cell Tumour of the spine, Dr Tan Li Mei
  8. (2012) Outcome of patients with bone metastases treated with palliative radiotherapy in ummc between january 2006 and december 2014., Dr Ina Shaliny Duraisamy
  9. (2012) Hormonal treatment and manipulation in metastatic prostate cancer, Dr Prathepamalar Yehgambaram

TEACHING

Master
  1. (2021) MSE27300 - Advanced Clinical Training
  2. (2021) MSE27230 - Part I Examination
  3. (2017) ONCOLOGY - Master of Clinical Oncology
  4. (2014) Oncological Emergencies
  5. (2014) NO - Kursus Phlebotomy, Venipuncture and Iv Medication Therapy Untuk Pegawai Perubatan Siswazah
  6. (2013) Master in Clinical Oncology
  7. (2013) Kursus Phlebotomy, Venipuncture and Iv Medication Therapy Untuk Pegawai Perubatan Siswazah
Bachelor
  1. (2015) MTEJ2112 - Basic Medical Science Iv: General Management of Cancer Patient
  2. (2014) General Management of Cancer Patient
  3. (2013) Pain and Its Management
  4. (2012) Clinical Oncology and Principles of Radiotherapy

SOCIAL RESPONSIBILITY ACTIVITIES

  • Giving a Talk and Q&Amp;a Session With Patients and Support Group, (26 Oct 2024 - 26 Oct 2024) (National)
  • Bike Ride Challenge to Raise Awareness On Prostate Cancer and Collect Charity or Donation, (02 Dec 2023 - 02 Dec 2023) (National)
  • Organising Committee for Lung Cancer Awareness Month, (01 Nov 2023 - 30 Nov 2023) (National)
  • Committee for Lung Cancer Awareness Month At Ummc, (01 Nov 2022 - 30 Nov 2022) (National)
  • Chairperson- Breakfast At UM Health: The Masquerader, (27 Jul 2022 - 27 Jul 2022) (University)
  • Subcommittee Panel for Clinical Oncology Accreditation Nsr, (03 Jan 2022 - 30 Dec 2023) (National)
  • Bicara Kanser Interview With Rtm1, (19 Dec 2020 - 19 Dec 2020)
  • Ummc Lung Cancer Patient Diary, (20 Oct 2020 - 20 Oct 2020)
  • Kinabalu Park World Heritage, (25 Sep 2020 - 25 Sep 2020)
  • City Cancer Challenge Committee Member, (03 Feb 2020 - 31 Dec 2022) (National)
  • Malaysia Women Marathon 2019 Half Marathon 21.0975km, (03 Mar 2019 - 03 Mar 2019)
  • Bernama Interview: Umsc Multidisiplinary Team Approach On Lung Cancer Gives Hope to Patient, (25 Jan 2019 - 25 Jan 2019)
  • E10 Npe Highway Challenge (2nd Series), (29 Jul 2018 - 29 Jul 2018)
  • Women Half Marathon, (04 Mar 2018 - 04 Mar 2018)
  • Npe Run 2017 Ijm Allianz Duo Highway Run, (10 Sep 2017 - 10 Sep 2017)
  • Chair for The Clinical Oncology Dept Family Day 2017, (03 Jul 2017 - 17 Dec 2017)
  • Malaysia Women Marathon, (05 Mar 2017 - 05 Mar 2017)
  • Healthcare Professional Run 2016-Participant/Runner, (09 Oct 2016 - 09 Oct 2016)
  • Ummc 3rd Breast Cancer Forum, (09 Oct 2016 - 09 Oct 2016)
  • Prostate Cancer Blue Cap Relay Run- Participant/Runner, (29 Nov 2015 - 29 Nov 2015)
  • Article On Prostate Cancer in The Sunday Star 22 November 2015 : Choice in Prostate Cancer - Decoding Your Choice of Care for Prostate Cancer., (22 Nov 2015 - 22 Nov 2015)
  • Speaker for 2nd Ummc Breast Cancer Public Forum Oct 2015., (25 Oct 2015 - 25 Oct 2015)
  • Lst Value and Cost Effectiveness in Cancer Seminar, (23 Nov 2014 - 24 Nov 2014)
  • Advanced Breast Cancer Workshop, (25 Oct 2014 - 25 Oct 2014)
  • Advanced Breast Cancer Workshop, (18 Oct 2014 - 18 Oct 2014)
  • Larian Gegar UM, (04 May 2014)
  • Malaysia Women Marathon Run, (16 Mar 2014)
  • International Women's Day Run, (09 Mar 2014)
  • Penang Bridge International, (17 Nov 2013 - 17 Nov 2013)
  • Night Run 2013, (07 Sep 2013 - 07 Sep 2013)
  • Sundown Marathon 2013, (31 May 2013 - 02 Jun 2013)
  • Makna Charity Run., (31 Mar 2013 - 31 Mar 2013)

COURSE ATTENDED

Internal/ External Course
EXTERNAL COURSE
  1. 2019 GENITOURINARY CANCERS SYMPOSIUM, San Francisco (14 Feb 2019 - 15 Feb 2019)
CONFERENCE
  1. INVESTIGATOR MEETING FOR STUDY MK3475-676 , Warsaw Poland (16 Jan 2019 - 19 Jan 2019)
  2. CT-P16 3.1 STUDY INVESTIGATOR MEETING, Intercontinental Hotel Kuala Lumpur (20 Feb 2019 - 21 Feb 2019)